ROMA指数在妇科盆腔肿瘤高危人群风险评估的意义

Significance of ROMA index in risk assessment of high risk population of gynecological pelvic tumors

目的 运用卵巢恶性肿瘤风险模型（ROMA指数）对盆腔肿瘤恶性风险进行评估.方法 采用电化学发光法免疫测定68例卵巢癌、54例子宫癌,242例卵巢良性病变、128例子宫肌腺瘤以及56例健康女性的血清HE4和CA125含量,计算患者ROMA值.结果 卵巢癌患者、子宫癌患者、卵巢良性病变、子宫良性肌腺瘤、健康体检女性血清HE4与 CA125含量分别为（291.8±63.26）与（463.2±288.2）、（175.6±45.5）与（513.7±138.5）、（34.6±16.2）与（61.5±9.6）、（32.4±10.7）与（82.6±29.7）、（31.9±11.7）pmol/L与（16.3±8.9）U/L.ROMA指数阳性灵敏度和特异性分别为89.71和96.48.结论 联合检测血清HE4和CA125比单一检测提高阳性检出率,ROMA指数在高风险患者的评估更直观,特异性更强,有利于高危人群的早期筛查和盆腔肿物的良恶鉴别.

Objective To evaluate the risk of malignant pelvic tumors by using the ovarian malignant tumor risk model（ROMA index）.Methods The serum levels of HE4 and CA125 in 68 cases of ovarian cancer,54 cases of uterine cancer,242 cases of benign ovarian lesions,128 cases of uterine muscle adenoma and 56 cases of healthy women were measured by electrochemical luminescence immunoassay.Results The patients with ovarian cancer,uterine cancer,ovarian benign lesions,benign uterine adenomyosis,healthy women serum HE4 and CA125 content were 291.8±63.26 and 463.2±288.2,175.6±45.5 and 513.7±138.5,34.6±16.2 and 61.5±9.6,32.4±10.7 and 82.6±29.7,31.9±11.7 pmol/l with 16.3±8.9 U/L.The positive sensitivity and specificity of ROMA were 89.71 and 96.48,respectively.Conclusion The combined detection of serum HE4 and CA125 increase the positive rate than single detection.The ROMA index in the evaluation of high risk patients more intuitive,more specific,early screening and differential diagnosis of benign and malignant pelvic tumors to the high-risk population.